VPS33A and mucopolysaccharidosis-plus syndrome: Thus, the drug does not seem to act on the MPSPS mutant VPS33A protein in a specific manner but may act directly on the GAG metabolic pathway and can potentially expand its applications to other diseases than the ultra-rare MPSPS.